October 17th 2025
Venetoclax with bortezomib and dexamethasone led to a median PFS of 23.4 months compared with 11.4 months with placebo in patients with R/R MM.
Managing Taste Changes and Weight Loss During Talquetamab Treatment
October 8th 2025Panelists discuss how patients can maintain their nutrition during talquetamab treatment by focusing on texture and food presentation when taste is impaired, using high-calorie options, and remembering that taste changes and dry mouth are temporary adverse effects that improve over time.
Practical Tips for Managing Nail and Skin Changes While Receiving Talquetamab
October 8th 2025Panelists discuss how specific talquetamab-related adverse effects such as skin peeling, nail changes, and rashes can be effectively managed through targeted interventions, including topical treatments, protective measures, and preventive strategies tailored to the drug's unique toxicity profile.
Developing a System-Wide Protocol for Talquetamab Toxicity Management
October 8th 2025Panelists discuss how health care providers can develop comprehensive management protocols for talquetamab-related toxicities by consulting with specialists, gathering patient feedback, and creating detailed handouts that empower patients to proactively manage adverse effects before they begin treatment.
Addressing Early Talquetamab Toxicity Concerns
October 7th 2025Panelists discuss how comprehensive patient education materials and manufacturer resources help patients prepare for and manage talquetamab adverse effects, with prior experience from chimeric antigen receptor (CAR) T-cell therapy providing valuable context for understanding potential complications such as cytokine release syndrome (CRS).
Real-World Efficacy and Safety Protocols for Bispecific Antibodies
October 7th 2025Panelists discuss how real-world data consistently show bispecific efficacy matching clinical trial results despite treating higher-risk patients, and how prophylactic interventions have reduced cytokine release syndrome severity.
Sequencing Strategies and Patient Selection for Bispecific Antibodies in RRMM
October 7th 2025Panelists discuss how CAR T-cell therapy should generally precede bispecifics when possible due to T-cell exhaustion concerns, though they agree there are virtually no absolute contraindications to bispecific therapy.
Extending Talquetamab Education Beyond the Hospital
October 7th 2025Panelists discuss how health care providers must actively educate local oncologists, emergency departments, and community centers about bispecific antibody management as these therapies move from inpatient to outpatient settings, ensuring proper recognition and treatment of adverse effects such as cytokine release syndrome (CRS).
Navigating Novel Therapies: ADCs, BsAbs, and CAR T in RRMM
September 30th 2025Panelists discuss how bispecifics are reversing the historical paradigm of diminishing returns in relapsed/refractory multiple myeloma, achieving 60% to 70% response rates lasting over a year in heavily pretreated patients.
Treatment Decision-Making in Multiple Myeloma at First and Subsequent Relapses
September 30th 2025Panelists discuss how patient preferences for treatment-free intervals are increasingly important in therapy selection, with bispecifics offering potential for response-adapted dosing and early discontinuation while maintaining remissions.
Coordinated Health Care Teams and Caregiver Support
September 30th 2025Panelists discuss how successful talquetamab treatment requires coordinated care between inpatient and outpatient teams, comprehensive caregiver preparation including education materials and emergency contact information, and access to multidisciplinary health care providers as needed.
Alan's Treatment Course and Quality-of-Life Goals
September 30th 2025Panelists discuss how expectations for treatment outcomes can become more positive over time through experience with multiple therapies, staying informed about clinical trials and new treatments, and focusing on quality of life as a primary treatment goal alongside disease control.
Connecting With Multiple Myeloma Support Groups and Online Resources
September 23rd 2025Panelists discuss how caregivers can navigate the initial shock of a myeloma diagnosis by seeking reliable information from trusted medical websites, connecting with local support groups, and accessing resources from organizations such as the International Myeloma Foundation (IMF), Multiple Myeloma Research Foundation (MMRF), and patient advocacy groups.
Alan's Multiple Myeloma Journey: Facing a New Diagnosis
September 23rd 2025Panelists discuss how Alan Plisskin's multiple myeloma diagnosis began with severe back and hip pain, progressed through life-threatening complications, including seizures and vocal cord paralysis, and revealed extensive lytic lesions throughout his body that required immediate intensive treatment.